254 related articles for article (PubMed ID: 26604096)
21. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
[TBL] [Abstract][Full Text] [Related]
22. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
[TBL] [Abstract][Full Text] [Related]
24. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
[TBL] [Abstract][Full Text] [Related]
25. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells.
Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J
Cell Stress Chaperones; 2021 May; 26(3):495-504. PubMed ID: 33629253
[TBL] [Abstract][Full Text] [Related]
26. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
[TBL] [Abstract][Full Text] [Related]
27. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
[TBL] [Abstract][Full Text] [Related]
28. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
Stühmer T; Zöllinger A; Siegmund D; Chatterjee M; Grella E; Knop S; Kortüm M; Unzicker C; Jensen MR; Quadt C; Chène P; Schoepfer J; García-Echeverría C; Einsele H; Wajant H; Bargou RC
Leukemia; 2008 Aug; 22(8):1604-12. PubMed ID: 18480838
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
Lee KH; Lee JH; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Cancer Sci; 2011 Jul; 102(7):1388-95. PubMed ID: 21453385
[TBL] [Abstract][Full Text] [Related]
30. The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo.
Wendel T; Zhen Y; Suo Z; Bruheim S; Wiedlocha A
Exp Cell Res; 2016 Jan; 340(2):220-6. PubMed ID: 26748184
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
33. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract][Full Text] [Related]
34. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
[TBL] [Abstract][Full Text] [Related]
35. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.
Stingl L; Niewidok N; Müller N; Selle M; Djuzenova CS; Flentje M
Strahlenther Onkol; 2012 Jun; 188(6):507-15. PubMed ID: 22441439
[TBL] [Abstract][Full Text] [Related]
36. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
[TBL] [Abstract][Full Text] [Related]
37. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
38. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
[TBL] [Abstract][Full Text] [Related]
39. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
40. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
